These results indicate that DFO suppresses tumor progression in ESCC PDX models by targeting TAOK1 and enhancing p53 activity, providing a potential therapeutic strategy for treating ESCC. The gene discussed is TP53; the disease is esophageal squamous cell carcinoma.